Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

1989 • 467 citations

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

1990 • 217 citations

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

1978 • 166 citations

Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.

1990 • 83 citations

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

1986 • 73 citations

Etoposide (VP-16) in the treatment of lung cancer

1983 • 50 citations

Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)

1988 • 27 citations

Phase II study of teniposide in small cell carcinoma of the lung.

1984 • 25 citations

Treatment of small cell bronchogenic carcinoma with VM-26.

1979 • 21 citations

The design of phase II trials

1989 • 9 citations